<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pract</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pract</journal-id><journal-id journal-id-type="publisher-id">clinpract</journal-id><journal-title-group><journal-title>Clinics and Practice</journal-title></journal-title-group><issn pub-type="ppub">2039-7275</issn><issn pub-type="epub">2039-7283</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10453449</article-id><article-id pub-id-type="pmid">37623259</article-id><article-id pub-id-type="doi">10.3390/clinpract13040078</article-id><article-id pub-id-type="publisher-id">clinpract-13-00078</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Mobile Health Solutions for Prostate Cancer Diagnostics&#x02014;A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7957-5031</contrib-id><name><surname>Moghul</surname><given-names>Masood</given-names></name><xref rid="af1-clinpract-13-00078" ref-type="aff">1</xref><xref rid="af2-clinpract-13-00078" ref-type="aff">2</xref><xref rid="c1-clinpract-13-00078" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Cazzaniga</surname><given-names>Walter</given-names></name><xref rid="af1-clinpract-13-00078" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Croft</surname><given-names>Fionnuala</given-names></name><xref rid="af1-clinpract-13-00078" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kinsella</surname><given-names>Netty</given-names></name><xref rid="af1-clinpract-13-00078" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Cahill</surname><given-names>Declan</given-names></name><xref rid="af1-clinpract-13-00078" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>Nicholas David</given-names></name><xref rid="af1-clinpract-13-00078" ref-type="aff">1</xref><xref rid="af2-clinpract-13-00078" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>L&#x000f3;pez</surname><given-names>Jos&#x000e9; I.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-clinpract-13-00078"><label>1</label>Department of Urology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK</aff><aff id="af2-clinpract-13-00078"><label>2</label>Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SW3 6JB, UK</aff><author-notes><corresp id="c1-clinpract-13-00078"><label>*</label>Correspondence: <email>masood.moghul@doctors.org.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2023</year></pub-date><volume>13</volume><issue>4</issue><fpage>863</fpage><lpage>872</lpage><history><date date-type="received"><day>24</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>10</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Prostate cancer, the most common cause of cancer in men in the UK and one of the most common around the world to date, has no consensus on screening. Multiple large-scale trials from around the world have produced conflicting outcomes in cancer-specific and overall mortality. A main part of the issue is the PSA test, which has a high degree of variability, making it challenging to set PSA thresholds, as well as limited specificity. Prostate cancer has a predisposition in men from black backgrounds, and outcomes are worse in men of lower socioeconomic groups. Mobile targeted case finding, focusing on high-risk groups, may be a solution to help those that most need it. The aim of this systematic review was to review the evidence for mobile testing for prostate cancer. A review of all mobile screening studies for prostate cancer was performed in accordance with the Cochrane guidelines and the PRISMA statement. Of the 629 unique studies screened, 6 were found to be eligible for the review. The studies dated from 1973 to 2017 and came from four different continents, with around 30,275 men being screened for prostate cancer. Detection rates varied from 0.6% in the earliest study to 8.2% in the latest study. The challenge of early diagnosis of potentially lethal prostate cancer remains an issue for developed and low- and middle-income countries alike. Although further studies are needed, mobile screening of a targeted population with streamlined investigation and referral pathways combined with raising awareness in those communities may help make the case for screening for prostate cancer.</p></abstract><kwd-group><kwd>prostate cancer</kwd><kwd>mobile clinic</kwd><kwd>community setting</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-clinpract-13-00078"><title>1. Introduction</title><p>Prostate cancer is the most common cancer in men in the UK, with over 50,000 new cases diagnosed and 12,000 lives lost to prostate cancer in the UK each year [<xref rid="B1-clinpract-13-00078" ref-type="bibr">1</xref>]. This is of particular concern for black African and African Caribbean men, who carry a one in four risk of developing prostate cancer (compared with one in six men overall) [<xref rid="B2-clinpract-13-00078" ref-type="bibr">2</xref>], and for men with a family history of the disease. As cancers tend to arise in the peripheries of the prostate gland, there may be few or no symptoms, even from locally advanced disease, until very late on. Even with symptoms, they can easily be conflated with benign disease or ignored as a typical feature of the ageing process.</p><p>Early diagnosis and treatment are potentially lifesaving for a range of conditions, with late presentation being a major cause of death from cancer. A range of barriers to accessing healthcare have been identified, including low education levels [<xref rid="B3-clinpract-13-00078" ref-type="bibr">3</xref>] (which may result in a lack of knowledge of relevant symptoms), logistical difficulties in accessing healthcare (for example, due to anti-social working hours and geographical locations) [<xref rid="B4-clinpract-13-00078" ref-type="bibr">4</xref>], and financial considerations (particularly in insurance-dependent healthcare systems). These issues are often exacerbated in low- and middle-income countries (LMICs), as demonstrated by the severe burden of prostate cancer in sub-Saharan Africa [<xref rid="B5-clinpract-13-00078" ref-type="bibr">5</xref>,<xref rid="B6-clinpract-13-00078" ref-type="bibr">6</xref>], which is thought to be increasing [<xref rid="B5-clinpract-13-00078" ref-type="bibr">5</xref>]. The wider effects of health inequalities affect all in society, with a recent Deloitte report estimating the annual healthcare US expenditure due to health inequities at $320 billion, which is set to rise to $1 trillion or more by 2040 [<xref rid="B7-clinpract-13-00078" ref-type="bibr">7</xref>].</p><p>Despite many advances in the field of early diagnosis of prostate cancer, significant issues remain. PSA testing remains at the forefront of early diagnostic testing despite its unreliability as a screening tool for prostate cancer, making its widespread use contentious. A key issue in using PSA as a screening tool comes from the definition of what a &#x02018;normal&#x02019; PSA is. Oesterling&#x02019;s age-specific PSA ranges from 1993 are still in use today [<xref rid="B8-clinpract-13-00078" ref-type="bibr">8</xref>]. PSA is not only elevated in prostate cancer but can also be elevated due to benign growth of the prostate, urinary tract obstruction, infection, or prostatic inflammation. Having a higher PSA threshold for investigation increases the positive predictive value for detecting prostate cancer but lowers the negative predictive value, and vice versa. For example, a study by Gerstenbluth documented a PPV of 98.5% for PSA in detecting prostate cancer with a PSA of 50 ng/mL or above [<xref rid="B9-clinpract-13-00078" ref-type="bibr">9</xref>], but a threshold this high, while largely eliminating false positives, would also miss the majority of clinically significant cancers.</p><p>The evidence for screening remains controversial. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial [<xref rid="B10-clinpract-13-00078" ref-type="bibr">10</xref>] from the USA looked at systematic vs. opportunistic screening in over 76,000 men. Using a PSA threshold of over 4 and 7&#x02013;10 years of follow-up, no significant difference in mortality from prostate cancer was found between the screened and non-screened arms. However, the study had high rates of contamination between the two groups, with an estimated 74% of the control group subject to at least one routine PSA test during the trial (95% in the intervention arm) and around 50% of men in the control group tested each year [<xref rid="B11-clinpract-13-00078" ref-type="bibr">11</xref>].</p><p>The European Randomised Study of Screening for Prostate Cancer (ERSPC) has been studying 186,000 men aged 55 to 69 in Europe since 1992. In its 16th year of follow-up [<xref rid="B12-clinpract-13-00078" ref-type="bibr">12</xref>], results show a 20% reduction in cancer-specific survival, and the number needed to treat is now similar to that observed in breast cancer screening [<xref rid="B13-clinpract-13-00078" ref-type="bibr">13</xref>], strengthening the argument for prostate cancer screening. A total of seven studies in different regions of Europe were included, with each study using different screening criteria, treatment protocols, interval timing, and PSA thresholds (between 3 ug/L and 4 ug/L), which threatens the credibility of its conclusions.</p><p>The use of pre-biopsy MRI scanning has enhanced diagnostic rates and reduced unnecessary biopsies [<xref rid="B14-clinpract-13-00078" ref-type="bibr">14</xref>,<xref rid="B15-clinpract-13-00078" ref-type="bibr">15</xref>], and the transition from transrectal to transperineal approaches has further reduced morbidity from biopsies [<xref rid="B16-clinpract-13-00078" ref-type="bibr">16</xref>]. While these achievements are notable, case finding remains an issue, with nearly 20% of men in the UK diagnosed with metastatic disease [<xref rid="B17-clinpract-13-00078" ref-type="bibr">17</xref>]. As these men account for at least half of those who eventually die from prostate cancer, reducing the rate of metastatic presentation is key to reducing mortality. New biomarkers once heralded as potential game changers have not yet successfully displaced the use of PSA in routine testing. Liquid biopsies may yet yield further benefit but remain some way from routine clinical use.</p><p>The National Institute for Health and Care Excellence (NICE)&#x02019;s guidelines in the UK suggest a risk-stratified approach along with patient counselling. The guidelines recommend consideration of a PSA test for men with lower urinary tract symptoms, haematuria, or erectile dysfunction [<xref rid="B18-clinpract-13-00078" ref-type="bibr">18</xref>]. As already noted, there is a poor correlation between symptoms and the presence of prostate cancer [<xref rid="B19-clinpract-13-00078" ref-type="bibr">19</xref>], with many men diagnosed with clinically significant prostate cancer experiencing no symptoms. Routine systematic screening is also not currently recommended by either the AUA [<xref rid="B20-clinpract-13-00078" ref-type="bibr">20</xref>] or EAU [<xref rid="B21-clinpract-13-00078" ref-type="bibr">21</xref>].</p><p>Although findings from large-scale prostate cancer screening trials have found equivocal results, targeted screening programmes for high-risk populations may yet yield benefits. Mobile health units may enable increased access for groups that otherwise struggle to access healthcare. This may be especially advantageous in LMICs, where healthcare infrastructure is even more sparse. Screening for a range of diseases in combination with health promotion may increase economic viability and provide a wider range of health benefits for these populations. Mobile screening for other diseases (e.g., HIV) has already shown feasibility and economic viability [<xref rid="B22-clinpract-13-00078" ref-type="bibr">22</xref>], and combining mobile health solutions with a risk-stratified approach targeting high-risk populations may help to crack the nut that is early diagnosis of prostate cancer.</p><p>The aim of this systematic review was to review the evidence for mobile testing for prostate cancer.</p></sec><sec sec-type="methods" id="sec2-clinpract-13-00078"><title>2. Methods</title><p>The review was performed in accordance with the Cochrane guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [<xref rid="B23-clinpract-13-00078" ref-type="bibr">23</xref>].</p><p>The following bibliographic databases were searched for studies on mobile screening for prostate cancer up to August 2022: MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and the WHO Global Health Library. The search was conducted on 1 August 2022.</p><p>No restrictions were placed on language, study design, study location, or participants. All studies that offered tests for prostate cancer using mobile methods were included. Published articles in peer-reviewed journals or thesis dissertations were included, as well as hand-searching individual urological journals, citations, and reference lists. Conference abstracts/posters, review articles, and opinion pieces were excluded. Search terms included (but were not limited to) the following: &#x02018;prostate&#x02019;, &#x02018;cancer&#x02019;, &#x02018;screening&#x02019;, &#x02018;mobile&#x02019;, &#x02018;movable&#x02019;, and &#x02018;traveling&#x02019;. Boolean operators (AND, OR) were employed to augment the search process. Details of the search strategy are included in <xref rid="app1-clinpract-13-00078" ref-type="app">Supplementary File S1</xref>.</p><p>Titles and abstracts were reviewed to assess potential studies, with full texts of eligible articles screened by one author and verified by a second. In the event of any disagreements between the authors, they were resolved by discussion or consultation with a third author. Two authors independently reviewed all full-text articles, with data extracted onto a standardised spreadsheet and validation by each reviewer of the other&#x02019;s data. </p><p>Data extracted from the studies included the following: study design, country, population details, number of men screened, type of mobile screening facility (e.g., mobile van or other type of temporary facility), and performance measures, including the rate of screening tests, rate of follow-up loss (i.e., patients referred for further investigations but lost to follow-up), number of detected cases, and characteristics of detected cases, including staging and extent of disease. The results were synthesised into a tabulated format.</p><p>A statistical analysis or meta-analysis was not possible due to the heterogeneity of study designs and endpoints. Studies were, therefore, analysed qualitatively in terms of various key parameters, such as study type, design, length, men screened for prostate cancer, average age, method of mobile testing, prostate cancer test, PSA thresholds, percentage investigated, further investigations performed, loss of follow-up, biopsy rates, prostate cancer detection rates, stage of disease, and grade of disease. The quality of the studies was assessed using the MMAT (Mixed Methods Appraisal Tool) [<xref rid="B24-clinpract-13-00078" ref-type="bibr">24</xref>], with independent verification by two authors.</p></sec><sec sec-type="results" id="sec3-clinpract-13-00078"><title>3. Results</title><p>The initial search identified 875 articles, with 2 additional articles identified through other means. After excluding duplicates, 629 unique articles were identified. Analysis of titles and abstracts narrowed this down to 16 articles, for which the full text was reviewed. Of these, six studies met the inclusion criteria. A PRISMA flow diagram illustrating the search process is shown in <xref rid="clinpract-13-00078-f001" ref-type="fig">Figure 1</xref>.</p><p>A summary of these six studies (published between 1973 and 2020) is shown in <xref rid="clinpract-13-00078-t001" ref-type="table">Table 1</xref>. Overall, at least 30,275 men were screened (with Lynch et al. [<xref rid="B25-clinpract-13-00078" ref-type="bibr">25</xref>] not reporting individual numbers of men and women screened). Three studies were purely focused on screening for prostate cancer, with the other three being multi-cancer screening studies. Three were based in the USA (of which one targeted the African American community [<xref rid="B26-clinpract-13-00078" ref-type="bibr">26</xref>]), with one each from Africa, the Far East, and South America. The study designs are reported in <xref rid="clinpract-13-00078-t001" ref-type="table">Table 1</xref>, but the majority were cross-sectional, with results published of a descriptive nature. One study had a prolonged follow-up with prospective data. Performance measures are also shown in <xref rid="clinpract-13-00078-t001" ref-type="table">Table 1</xref>; however, the initial studies were more focused on proving the proof of concept and the calculation of potential health economics. Due to the prolonged period between studies, the type of screening varied drastically, beginning with just a rectal exam before moving onto transrectal ultrasound and then finally PSA blood tests combined with a digital rectal exam. The overall score from the methodological quality review was 76% across the six studies assessed, indicating a reasonable level of quality, although direct comparisons are challenging due to heterogeneity.</p><p>The interaction between fixed healthcare assets (hospitals, clinics, etc.) and the mobile service varied between the studies depending on existing infrastructure and the type of community being targeted (rural versus urban). Ashorobi et al. [<xref rid="B26-clinpract-13-00078" ref-type="bibr">26</xref>] began the project in static centres before moving onto a mobile service, while Jatho et al. [<xref rid="B27-clinpract-13-00078" ref-type="bibr">27</xref>] ran simultaneous hospital and mobile-based screening services, with comparisons between the two showing a significantly higher detection rate of prostate cancer in the mobile screening setting (8.2% vs. 7.1%, chi-squared test: <italic toggle="yes">p</italic> &#x0003c; 0.05).</p><p>Health economic data from the included studies are limited. However, Jatho et al. [<xref rid="B27-clinpract-13-00078" ref-type="bibr">27</xref>] noted that with an average screening cost of $30 USD, treatment costs for treating advanced disease for one patient are 600&#x000d7; higher ($18,000 USD).</p></sec><sec sec-type="discussion" id="sec4-clinpract-13-00078"><title>4. Discussion</title><p>Major screening trials for prostate cancer have been carried out in unselected populations in high-income countries with generally good healthcare provision, often with men from the upper end of economic groups overrepresented and with disproportionately lower levels of ethnic minorities [<xref rid="B10-clinpract-13-00078" ref-type="bibr">10</xref>,<xref rid="B28-clinpract-13-00078" ref-type="bibr">28</xref>]. Worse outcomes for prostate cancer in ethnic minorities and lower socio-economic groups highlight the importance of investigating and developing methods to overcome these barriers [<xref rid="B29-clinpract-13-00078" ref-type="bibr">29</xref>,<xref rid="B30-clinpract-13-00078" ref-type="bibr">30</xref>,<xref rid="B31-clinpract-13-00078" ref-type="bibr">31</xref>]. In LMICs, there are different issues, with poorer access to healthcare and lower education levels leading to late-stage presentations being the norm. </p><p>Even in high-income settings, too many patients are still found to have cancer after an emergency presentation&#x02014;around 30% for cancers overall in the UK [<xref rid="B32-clinpract-13-00078" ref-type="bibr">32</xref>] (although the figure for prostate cancer is closer to 10% [<xref rid="B33-clinpract-13-00078" ref-type="bibr">33</xref>,<xref rid="B34-clinpract-13-00078" ref-type="bibr">34</xref>]). For men diagnosed with prostate cancer, 8% were found to have attended emergency departments at least once in the 30 days prior to diagnosis [<xref rid="B35-clinpract-13-00078" ref-type="bibr">35</xref>]. Furthermore, presentation at a late stage means that treatment is less likely to be successful and will certainly carry more morbidity for the patient and cost for the healthcare system. </p><p>The NHS sees many patients accessing cancer care at a late stage. Reducing this trend is a key objective of the NHS Long Term Plan [<xref rid="B36-clinpract-13-00078" ref-type="bibr">36</xref>], with similar goals within the US Cancer Moonshot programme [<xref rid="B37-clinpract-13-00078" ref-type="bibr">37</xref>] and the European Union&#x02019;s Cancer Beating Plan [<xref rid="B38-clinpract-13-00078" ref-type="bibr">38</xref>]. The recent COVID-19 pandemic has led to a sharp decline in referrals for cancer diagnostics [<xref rid="B39-clinpract-13-00078" ref-type="bibr">39</xref>], suggesting that there may be a growing reservoir of undiagnosed cancer in the community. Mobile clinics can potentially be a model for alleviating this, where their presence in a community setting makes &#x02018;seeking advice on health issues&#x02019; less daunting, more normal, and easily accessible.</p><p>A key part of any mobile screening service is raising awareness among the target community. This is particularly important as these initiatives are often new and patients may not be fully aware of the services offered. In the earliest studies, Lynch et al. [<xref rid="B25-clinpract-13-00078" ref-type="bibr">25</xref>] mentioned using local community leaders and physicians to coordinate this. Faria et al. [<xref rid="B40-clinpract-13-00078" ref-type="bibr">40</xref>] in Brazil had a programme for raising awareness that was conducted two weeks prior to the mobile service coming to a particular area. This consisted of the distribution of printed materials, messaging via local radio stations, and making children in schools more aware (presumably to then inform parents). Ashorobi et al. [<xref rid="B26-clinpract-13-00078" ref-type="bibr">26</xref>] used multiple media outlets as well as community engagement via churches, community centres, and barber shops, with a specific focus on targeting men from the African American community. Jatho et al. [<xref rid="B27-clinpract-13-00078" ref-type="bibr">27</xref>] in Uganda utilised a similar mixture of media messaging with local community infrastructure. </p><p>Studies prior to PSA development clearly suffer from much lower detection rates. Once PSA testing is involved, the detection rates begin to approach those of other screening studies; for comparison, the PLCO study had a detection rate of around 1.4% after one screening round [<xref rid="B10-clinpract-13-00078" ref-type="bibr">10</xref>], and the first screening phase of the CAP trial had a rate of 3.3% [<xref rid="B41-clinpract-13-00078" ref-type="bibr">41</xref>] (18-month follow-up).</p><p>Despite the consistency in the utilisation of PSA in the three later studies, the investigation criteria still differ widely due to PSA thresholds and the use of free-to-total ratios in one study and no mention of PSA thresholds in another. All studies used digital rectal examinations of the prostate as a screening tool (with the Japanese study using a transrectal ultrasound scan), still showing their potential importance, particularly in LMICs. Faria et al. [<xref rid="B40-clinpract-13-00078" ref-type="bibr">40</xref>] showcased this further, with 19.7% of their prostate cancer diagnoses coming from men with an abnormal DRE but PSA levels below threshold. </p><p>Notably, Jatho et al. [<xref rid="B27-clinpract-13-00078" ref-type="bibr">27</xref>] compared diagnostic rates from their mobile service against hospital-based screening and found them to be significantly higher, suggesting that the mobile-targeted approach can provide improved access for higher-risk men. The 8.2% detection rate from this study was strikingly higher than the other studies, from which rates were calculable, perhaps due to the increased risk seen in black men. Although there are vast ethnic variations within Africa that as yet remain incompletely understood, targeted screening of high-risk populations through a mobile approach may increase detection rates in larger-scale studies.</p><p>Contamination is a concern in all screening studies. With the limited data available, prior PSA testing was only documented in the Brazilian study, with around 30% of men having had a previous DRE and 30% having had a previous PSA. Furthermore, some studies did not separate results from fixed and mobile clinics, making interpretation challenging. Loss of follow-up is also an issue, particularly in the study by Ashrobi et al. [<xref rid="B26-clinpract-13-00078" ref-type="bibr">26</xref>], with a 60% loss of patients after a referral was recommended, which may have adversely affected their detection rate.</p><p>A key principle of mobile screening has been a multimodal publicity campaign prior to the arrival of the mobile screening service. Of note, the use of radio broadcasts and schoolchildren in LMICs may be important techniques to circumvent the issue of low literacy rates. Other awareness-raising methods (flyers, telemedicine, social media, etc.) may also be important in specific communities. The multipronged approach of increasing awareness in the desired community, combined with providing ease of access to the screening service, seems to be a successful approach for maximising engagement, although there is limited information about the demand generated from these studies.</p><p>Although mobile services have been shown to have many uses, they may not be appropriate for all areas. Large buses or trailers may have more logistical challenges in urban areas than rural ones. Combining approaches with fixed clinical assets (e.g., clinic rooms or nursing rooms) with mobile services is likely to be beneficial when covering wide areas with diverse infrastructure set-ups. A further possibility is the creation of &#x02018;pop-up&#x02018; clinics in units such as unused shops or community centres. Mobile screening operations should strive to minimise potential delays in the referral pathway and the loss of follow-up that may occur due to delays between the screening test and the dissemination of results and the availability of further tests and treatments. The use of point-of-care blood testing to provide rapid PSA results can improve diagnostic times further and reduce the administrative burden resulting from delayed laboratory results. A fully integrated plan with aspects of education, awareness-raising, rapid diagnosis, and treatment is required. </p><p>Developments in pre-biopsy multiparametric MRI scans and evolving biopsy techniques (transperineal with MRI targeting) are likely to increase the detection rates of clinically significant cancers further, although applicability in LMICs may be limited at present. These developments may increase upfront costs (e.g., MRI scans) but reduce the rates of unnecessary biopsies and clinically insignificant disease [<xref rid="B14-clinpract-13-00078" ref-type="bibr">14</xref>,<xref rid="B15-clinpract-13-00078" ref-type="bibr">15</xref>]. Further studies looking at mobile techniques in conjunction with modern rapid diagnostic practises (including novel biomarkers and genetics) may yield further information and make a more comprehensive economic argument for targeted screening for prostate cancer. Limitations of these studies include a lack of information about the demand generated from awareness campaigns, cancer staging and grading information, and patient satisfaction data to showcase patient perceptions of mobile screening.</p><table-wrap position="anchor" id="clinpract-13-00078-t001"><object-id pub-id-type="pii">clinpract-13-00078-t001_Table 1</object-id><label>Table 1</label><caption><p>Illustrating key findings from all studies included in the review.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Type &#x00026; Quality Score</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Length</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Men Screened for PCa</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Av. Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method of Mobile Testing</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prostate Cancer Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PSA Thresholds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% Further Investigated</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% Loss of Follow-Up</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biopsy Rates</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% PCa Detection Rates (n)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage of Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Grade</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lynch et al. [<xref rid="B25-clinpract-13-00078" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1973</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantitative Descriptive<break/>MMAT: 40%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 year</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3040 men and women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Custom built trailer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified, likely rectal exam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (rate not calculatable)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lynch et al. [<xref rid="B42-clinpract-13-00078" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1976</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantitative Descriptive<break/>MMAT: 60%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-cancer </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1984</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Custom built trailer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified, likely rectal exam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.05%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Watanabe et al. [<xref rid="B43-clinpract-13-00078" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1984</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional<break/>MMAT: 60%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCa only</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 years </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">325 men in trials, then 1071 on mobile unit (total 1396)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preliminary model, then customised bus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transrectal ultrasound</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6% (8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Faria et al. [<xref rid="B40-clinpract-13-00078" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brazil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional<break/>MMAT: 80%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCa only</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mobile unit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSA (free and total), DRE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">initially &#x0003e;4, then &#x0003e;2.5 ng/mL if %fPSA &#x02264; 15%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.1% (2841)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.4% (1647)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1% (552) on first screen, overall rate including men screened multiple times: 3.7% (652)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.4% T1 17% T2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.5% GG1 32.5% &#x02265; GG2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ashorobi et al. [<xref rid="B26-clinpract-13-00078" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed: cross sectional and prospective<break/>MMAT: 80%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCa<break/>only</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 years </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4420</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Initially using fixed locations then bus. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSA, DRE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;2.5 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14% (609)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6% (116)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3% (144) overall</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jatho et al. [<xref rid="B27-clinpract-13-00078" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uganda</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional<break/>MMAT: 60%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-cancer </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4904</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mobile van and community-based assets.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PSA, DRE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.2% (404)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions" id="sec5-clinpract-13-00078"><title>5. Conclusions</title><p>Despite increasing research aimed at finding novel methods of targeting patients for disease screening, there is limited information on the use and efficacy of mobile screening for prostate cancer. Although intuitively mobile screening combined with an awareness-raising drive would seem to be a useful approach, the complexities of cancer screening in different communities, different countries, and differing types of residential areas make drawing blanket generalisations difficult. Despite this, some conclusions can be drawn. The feasibility of mobile screening for prostate cancer shows it is widely applicable across different countries, in both developed and LMICs. Due to the main cost of such services being staff, they may even be more economical in LMICs, where staffing costs are lower, although there may be increased challenges to further investigation and treatments.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-clinpract-13-00078"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/clinpract13040078/s1">https://www.mdpi.com/article/10.3390/clinpract13040078/s1</uri>, Supplementary File S1: PRISMA Checklist.</p><supplementary-material id="clinpract-13-00078-s001" position="float" content-type="local-data"><media xlink:href="clinpract-13-00078-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualisation, M.M., F.C., N.K, D.C. and N.D.J.; methodology, M.M., N.K., W.C. and N.D.J.; analysis, M.M., W.C, N.K. and N.D.J.; writing&#x02014;original draft preparation, M.M.; writing&#x02014;review and editing, M.M., W.C., F.C., N.K., N.D.J. and D.C.; supervision, N.K., D.C. and N.D.J.; project administration, N.K., D.C. and N.D.J. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-clinpract-13-00078"><label>1.</label><element-citation publication-type="webpage"><article-title>Cancer Research UK</article-title><comment>Available online: <ext-link xlink:href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer" ext-link-type="uri">https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-01">(accessed on 1 March 2023)</date-in-citation></element-citation></ref><ref id="B2-clinpract-13-00078"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lloyd</surname><given-names>T.</given-names></name>
<name><surname>Hounsome</surname><given-names>L.</given-names></name>
<name><surname>Mehay</surname><given-names>A.</given-names></name>
<name><surname>Mee</surname><given-names>S.</given-names></name>
<name><surname>Verne</surname><given-names>J.</given-names></name>
<name><surname>Cooper</surname><given-names>A.</given-names></name>
</person-group><article-title>Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008&#x02013;2010</article-title><source>BMC Med.</source><year>2015</year><volume>13</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-015-0405-5</pub-id><?supplied-pmid 26224061?><pub-id pub-id-type="pmid">26224061</pub-id></element-citation></ref><ref id="B3-clinpract-13-00078"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raghupathi</surname><given-names>V.</given-names></name>
<name><surname>Raghupathi</surname><given-names>W.</given-names></name>
</person-group><article-title>The influence of education on health: An empirical assessment of OECD countries for the period 1995&#x02013;2015</article-title><source>Arch. Public Health</source><year>2020</year><volume>78</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s13690-020-00402-5</pub-id><?supplied-pmid 32280462?><pub-id pub-id-type="pmid">32280462</pub-id></element-citation></ref><ref id="B4-clinpract-13-00078"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kullgren</surname><given-names>J.T.</given-names></name>
<name><surname>McLaughlin</surname><given-names>C.G.</given-names></name>
<name><surname>Mitra</surname><given-names>N.</given-names></name>
<name><surname>Armstrong</surname><given-names>K.</given-names></name>
</person-group><article-title>Nonfinancial barriers and access to care for U.S. adults</article-title><source>Health Serv. Res.</source><year>2012</year><volume>47</volume><fpage>462</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1111/j.1475-6773.2011.01308.x</pub-id><pub-id pub-id-type="pmid">22092449</pub-id></element-citation></ref><ref id="B5-clinpract-13-00078"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seraphin</surname><given-names>T.P.</given-names></name>
<name><surname>Joko-Fru</surname><given-names>W.Y.</given-names></name>
<name><surname>Kamat&#x000e9;</surname><given-names>B.</given-names></name>
<name><surname>Chokunonga</surname><given-names>E.</given-names></name>
<name><surname>Wabinga</surname><given-names>H.</given-names></name>
<name><surname>Somdyala</surname><given-names>N.I.</given-names></name>
<name><surname>Manraj</surname><given-names>S.S.</given-names></name>
<name><surname>Ogunbiyi</surname><given-names>O.J.</given-names></name>
<name><surname>Dzamalala</surname><given-names>C.P.</given-names></name>
<name><surname>Finesse</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Rising Prostate Cancer Incidence in Sub-Saharan Africa: A Trend Analysis of Data from the African Cancer Registry Network</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2021</year><volume>30</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-1005</pub-id><?supplied-pmid 33033143?><pub-id pub-id-type="pmid">33033143</pub-id></element-citation></ref><ref id="B6-clinpract-13-00078"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bray</surname><given-names>F.</given-names></name>
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I.</given-names></name>
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Torre</surname><given-names>L.A.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B7-clinpract-13-00078"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>J.</given-names></name>
<name><surname>Batra</surname><given-names>N.</given-names></name>
<name><surname>Davis</surname><given-names>A.</given-names></name>
<name><surname>Rush</surname><given-names>B.</given-names></name>
<name><surname>Gerhardt</surname><given-names>W.</given-names></name>
</person-group><article-title>US health care can&#x02019;t afford health inequities</article-title><source>Deloitte Insights</source><year>2022</year></element-citation></ref><ref id="B8-clinpract-13-00078"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oesterling</surname><given-names>J.E.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S.J.</given-names></name>
<name><surname>Chute</surname><given-names>C.G.</given-names></name>
<name><surname>Guess</surname><given-names>H.A.</given-names></name>
<name><surname>Girman</surname><given-names>C.J.</given-names></name>
<name><surname>Panser</surname><given-names>L.A.</given-names></name>
<name><surname>Lieber</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges</article-title><source>JAMA</source><year>1993</year><volume>270</volume><fpage>860</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">7688054</pub-id></element-citation></ref><ref id="B9-clinpract-13-00078"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerstenbluth</surname><given-names>R.E.</given-names></name>
<name><surname>Seftel</surname><given-names>A.D.</given-names></name>
<name><surname>Hampel</surname><given-names>N.</given-names></name>
<name><surname>Oefelein</surname><given-names>M.G.</given-names></name>
<name><surname>Resnick</surname><given-names>M.I.</given-names></name>
</person-group><article-title>The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: Is biopsy always required?</article-title><source>J. Urol.</source><year>2002</year><volume>168</volume><fpage>1990</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)64279-6</pub-id><pub-id pub-id-type="pmid">12394692</pub-id></element-citation></ref><ref id="B10-clinpract-13-00078"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andriole</surname><given-names>G.L.</given-names></name>
<name><surname>Crawford</surname><given-names>E.D.</given-names></name>
<name><surname>Grubb</surname><given-names>R.L.</given-names></name>
<name><surname>Buys</surname><given-names>S.S.</given-names></name>
<name><surname>Chia</surname><given-names>D.</given-names></name>
<name><surname>Church</surname><given-names>T.R.</given-names></name>
<name><surname>Fouad</surname><given-names>M.N.</given-names></name>
<name><surname>Gelmann</surname><given-names>E.P.</given-names></name>
<name><surname>Kvale</surname><given-names>P.A.</given-names></name>
<name><surname>Reding</surname><given-names>D.J.</given-names></name>
<etal/>
</person-group><article-title>Mortality Results from a Randomized Prostate-Cancer Screening Trial</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>1310</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810696</pub-id><pub-id pub-id-type="pmid">19297565</pub-id></element-citation></ref><ref id="B11-clinpract-13-00078"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Etzioni</surname><given-names>R.</given-names></name>
<name><surname>Gulati</surname><given-names>R.</given-names></name>
<name><surname>Cooperberg</surname><given-names>M.R.</given-names></name>
<name><surname>Penson</surname><given-names>D.M.</given-names></name>
<name><surname>Weiss</surname><given-names>N.S.</given-names></name>
<name><surname>Thompson</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening</article-title><source>Med. Care</source><year>2013</year><volume>51</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1097/MLR.0b013e31827da979</pub-id><pub-id pub-id-type="pmid">23269114</pub-id></element-citation></ref><ref id="B12-clinpract-13-00078"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hugosson</surname><given-names>J.</given-names></name>
<name><surname>Roobol</surname><given-names>M.J.</given-names></name>
<name><surname>M&#x000e5;nsson</surname><given-names>M.</given-names></name>
<name><surname>Tammela</surname><given-names>T.L.</given-names></name>
<name><surname>Zappa</surname><given-names>M.</given-names></name>
<name><surname>Nelen</surname><given-names>V.</given-names></name>
<name><surname>Kwiatkowski</surname><given-names>M.</given-names></name>
<name><surname>Lujan</surname><given-names>M.</given-names></name>
<name><surname>Carlsson</surname><given-names>S.V.</given-names></name>
<name><surname>Talala</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer</article-title><source>Eur. Urol.</source><year>2019</year><volume>76</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2019.02.009</pub-id><pub-id pub-id-type="pmid">30824296</pub-id></element-citation></ref><ref id="B13-clinpract-13-00078"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hendrick</surname><given-names>R.E.</given-names></name>
<name><surname>Helvie</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Mammography screening: A new estimate of number needed to screen to prevent one breast cancer death</article-title><source>AJR Am. J. Roentgenol.</source><year>2012</year><volume>198</volume><fpage>723</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.2214/AJR.11.7146</pub-id><pub-id pub-id-type="pmid">22358016</pub-id></element-citation></ref><ref id="B14-clinpract-13-00078"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasivisvanathan</surname><given-names>V.</given-names></name>
<name><surname>Rannikko</surname><given-names>A.S.</given-names></name>
<name><surname>Borghi</surname><given-names>M.</given-names></name>
<name><surname>Panebianco</surname><given-names>V.</given-names></name>
<name><surname>Mynderse</surname><given-names>L.A.</given-names></name>
<name><surname>Vaarala</surname><given-names>M.H.</given-names></name>
<name><surname>Briganti</surname><given-names>A.</given-names></name>
<name><surname>Bud&#x000e4;us</surname><given-names>L.</given-names></name>
<name><surname>Hellawell</surname><given-names>G.</given-names></name>
<name><surname>Hindley</surname><given-names>R.G.</given-names></name>
<etal/>
</person-group><article-title>MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>1767</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1801993</pub-id><?supplied-pmid 29552975?><pub-id pub-id-type="pmid">29552975</pub-id></element-citation></ref><ref id="B15-clinpract-13-00078"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>H.U.</given-names></name>
<name><surname>El-Shater Bosaily</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>L.C.</given-names></name>
<name><surname>Gabe</surname><given-names>R.</given-names></name>
<name><surname>Kaplan</surname><given-names>R.</given-names></name>
<name><surname>Parmar</surname><given-names>M.K.</given-names></name>
<name><surname>Collaco-Moraes</surname><given-names>Y.</given-names></name>
<name><surname>Ward</surname><given-names>K.</given-names></name>
<name><surname>Hindley</surname><given-names>R.G.</given-names></name>
<name><surname>Freeman</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>815</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32401-1</pub-id><pub-id pub-id-type="pmid">28110982</pub-id></element-citation></ref><ref id="B16-clinpract-13-00078"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>J.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
</person-group><article-title>Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: A systematic review and meta-analysis</article-title><source>World J. Surg. Oncol.</source><year>2019</year><volume>17</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s12957-019-1573-0</pub-id><?supplied-pmid 30760274?><pub-id pub-id-type="pmid">30760274</pub-id></element-citation></ref><ref id="B17-clinpract-13-00078"><label>17.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>CR UK</collab>
</person-group><article-title>Early Diagnosis Hub: Proportion and Number of Cases Diagnosed at Stage IV (Bubble Chart)</article-title><comment>Available online: <ext-link xlink:href="https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/" ext-link-type="uri">https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-01">(accessed on 1 March 2023)</date-in-citation></element-citation></ref><ref id="B18-clinpract-13-00078"><label>18.</label><element-citation publication-type="webpage"><article-title>NICE Guidelines Prostate Cancer: How Should I Assess a Person with Suspected Prostate Cancer? Last Revised in February 2022</article-title><comment>Available online: <ext-link xlink:href="https://cks.nice.org.uk/topics/prostate-cancer/diagnosis/assessment/" ext-link-type="uri">https://cks.nice.org.uk/topics/prostate-cancer/diagnosis/assessment/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-01">(accessed on 1 March 2023)</date-in-citation></element-citation></ref><ref id="B19-clinpract-13-00078"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gnanapragasam</surname><given-names>V.J.</given-names></name>
<name><surname>Greenberg</surname><given-names>D.</given-names></name>
<name><surname>Burnet</surname><given-names>N.</given-names></name>
</person-group><article-title>Urinary symptoms and prostate cancer&#x02014;The misconception that may be preventing earlier presentation and better survival outcomes</article-title><source>BMC Med.</source><year>2022</year><volume>20</volume><elocation-id>264</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-022-02453-7</pub-id><?supplied-pmid 35922801?><pub-id pub-id-type="pmid">35922801</pub-id></element-citation></ref><ref id="B20-clinpract-13-00078"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carter</surname><given-names>H.B.</given-names></name>
<name><surname>Albertsen</surname><given-names>P.C.</given-names></name>
<name><surname>Barry</surname><given-names>M.J.</given-names></name>
<name><surname>Etzioni</surname><given-names>R.</given-names></name>
<name><surname>Freedland</surname><given-names>S.J.</given-names></name>
<name><surname>Greene</surname><given-names>K.L.</given-names></name>
<name><surname>Holmberg</surname><given-names>L.</given-names></name>
<name><surname>Kantoff</surname><given-names>P.</given-names></name>
<name><surname>Konety</surname><given-names>B.R.</given-names></name>
<name><surname>Murad</surname><given-names>M.H.</given-names></name>
<etal/>
</person-group><article-title>Early detection of prostate cancer: AUA Guideline</article-title><source>J. Urol.</source><year>2013</year><volume>190</volume><fpage>419</fpage><pub-id pub-id-type="doi">10.1016/j.juro.2013.04.119</pub-id><?supplied-pmid 23659877?><pub-id pub-id-type="pmid">23659877</pub-id></element-citation></ref><ref id="B21-clinpract-13-00078"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>EAU</collab>
</person-group><article-title>Guidelines</article-title><source>Edn. Presented at the EAU Annual Congress Amsterdam 2022</source><publisher-name>EAU</publisher-name><publisher-loc>Arnhem, The Netherlands</publisher-loc><isbn>978-94-92671-16-5</isbn></element-citation></ref><ref id="B22-clinpract-13-00078"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bassett</surname><given-names>I.V.</given-names></name>
<name><surname>Govindasamy</surname><given-names>D.</given-names></name>
<name><surname>Erlwanger</surname><given-names>A.S.</given-names></name>
<name><surname>Hyle</surname><given-names>E.P.</given-names></name>
<name><surname>Kranzer</surname><given-names>K.</given-names></name>
<name><surname>van Schaik</surname><given-names>N.</given-names></name>
<name><surname>Noubary</surname><given-names>F.</given-names></name>
<name><surname>Paltiel</surname><given-names>A.D.</given-names></name>
<name><surname>Wood</surname><given-names>R.</given-names></name>
<name><surname>Walensky</surname><given-names>R.P.</given-names></name>
<etal/>
</person-group><article-title>Mobile HIV screening in Cape Town, South Africa: Clinical impact, cost and cost-effectiveness</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e85197</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085197</pub-id><pub-id pub-id-type="pmid">24465503</pub-id></element-citation></ref><ref id="B23-clinpract-13-00078"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moher</surname><given-names>D.</given-names></name>
<name><surname>Liberati</surname><given-names>A.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.</given-names></name>
<name><surname>Altman</surname><given-names>D.G.</given-names></name>
<collab>PRISMA Group</collab>
</person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement</article-title><source>Ann. Intern. Med.</source><year>2009</year><volume>151</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-151-4-200908180-00135</pub-id><pub-id pub-id-type="pmid">19622511</pub-id></element-citation></ref><ref id="B24-clinpract-13-00078"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>Q.N.</given-names></name>
<name><surname>Pluye</surname><given-names>P.</given-names></name>
<name><surname>F&#x000e0;bregues</surname><given-names>S.</given-names></name>
<name><surname>Bartlett</surname><given-names>G.</given-names></name>
<name><surname>Boardman</surname><given-names>F.</given-names></name>
<name><surname>Cargo</surname><given-names>M.</given-names></name>
<name><surname>Dagenais</surname><given-names>P.</given-names></name>
<name><surname>Gagnon</surname><given-names>M.-P.</given-names></name>
<name><surname>Griffiths</surname><given-names>F.</given-names></name>
<name><surname>Nicolau</surname><given-names>B.</given-names></name>
<etal/>
</person-group><source>Mixed Methods Appraisal Tool (MMAT), Version 2018; Registration of Copyright (#1148552)</source><publisher-name>Canadian Intellectual Property Office, Industry Canada</publisher-name><publisher-loc>Gatineau, QC, Canada</publisher-loc></element-citation></ref><ref id="B25-clinpract-13-00078"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lynch</surname><given-names>H.</given-names></name>
<name><surname>Lynch</surname><given-names>J.</given-names></name>
<name><surname>Kraft</surname><given-names>C.</given-names></name>
</person-group><article-title>A new approach to cancer screening and education</article-title><source>Geriatrics</source><year>1973</year><volume>28</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">4702072</pub-id></element-citation></ref><ref id="B26-clinpract-13-00078"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashorobi</surname><given-names>O.S.</given-names></name>
<name><surname>Frost</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Roberson</surname><given-names>P.</given-names></name>
<name><surname>Lin</surname><given-names>E.</given-names></name>
<name><surname>Volk</surname><given-names>R.J.</given-names></name>
<name><surname>Lopez</surname><given-names>D.S.</given-names></name>
<name><surname>Jones</surname><given-names>L.A.</given-names></name>
<name><surname>Pettaway</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Prostate Cancer Education, Detection, and Follow-Up in a Community-Based Multiethnic Cohort of Medically Underserved Men</article-title><source>Am. J. Mens. Health</source><year>2017</year><volume>11</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1177/1557988315584794</pub-id><?supplied-pmid 25986045?><pub-id pub-id-type="pmid">25986045</pub-id></element-citation></ref><ref id="B27-clinpract-13-00078"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jatho</surname><given-names>A.</given-names></name>
<name><surname>Mugisha</surname><given-names>N.M.</given-names></name>
<name><surname>Kafeero</surname><given-names>J.</given-names></name>
<name><surname>Holoya</surname><given-names>G.</given-names></name>
<name><surname>Okuku</surname><given-names>F.</given-names></name>
<name><surname>Niyonzima</surname><given-names>N.</given-names></name>
</person-group><article-title>Mobile cancer prevention and early detection outreach in Uganda: Partnering with communities toward bridging the cancer health disparities through &#x0201c;asset-based community development model&#x0201d;</article-title><source>Cancer Med.</source><year>2020</year><volume>9</volume><fpage>7317</fpage><lpage>7329</lpage><pub-id pub-id-type="doi">10.1002/cam4.3387</pub-id><?supplied-pmid 32810394?><pub-id pub-id-type="pmid">32810394</pub-id></element-citation></ref><ref id="B28-clinpract-13-00078"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinsky</surname><given-names>P.F.</given-names></name>
<name><surname>Ford</surname><given-names>M.</given-names></name>
<name><surname>Gamito</surname><given-names>E.</given-names></name>
<name><surname>Higgins</surname><given-names>D.</given-names></name>
<name><surname>Jenkins</surname><given-names>V.</given-names></name>
<name><surname>Lamerato</surname><given-names>L.</given-names></name>
<name><surname>Tenorio</surname><given-names>S.</given-names></name>
<name><surname>Marcus</surname><given-names>P.M.</given-names></name>
<name><surname>Gohagan</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Enrollment of Racial and Ethnic Minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial</article-title><source>J. Natl. Med. Assoc.</source><year>2008</year><volume>100</volume><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/S0027-9684(15)31241-4</pub-id><?supplied-pmid 18390022?><pub-id pub-id-type="pmid">18390022</pub-id></element-citation></ref><ref id="B29-clinpract-13-00078"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoffman</surname><given-names>R.M.</given-names></name>
<name><surname>Gilliland</surname><given-names>F.D.</given-names></name>
<name><surname>Eley</surname><given-names>J.W.</given-names></name>
<name><surname>Harlan</surname><given-names>L.C.</given-names></name>
<name><surname>Stephenson</surname><given-names>R.A.</given-names></name>
<name><surname>Stanford</surname><given-names>J.L.</given-names></name>
<name><surname>Albertson</surname><given-names>P.C.</given-names></name>
<name><surname>Hamilton</surname><given-names>A.S.</given-names></name>
<name><surname>Hunt</surname><given-names>W.C.</given-names></name>
<name><surname>Potosky</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Racial and ethnic differences in advanced-stage prostate cancer: The Prostate Cancer Outcomes Study</article-title><source>J. Natl. Cancer Inst.</source><year>2001</year><volume>93</volume><fpage>388</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1093/jnci/93.5.388</pub-id><?supplied-pmid 11238701?><pub-id pub-id-type="pmid">11238701</pub-id></element-citation></ref><ref id="B30-clinpract-13-00078"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fedewa</surname><given-names>S.A.</given-names></name>
<name><surname>Etzioni</surname><given-names>R.</given-names></name>
<name><surname>Flanders</surname><given-names>W.D.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
<name><surname>Ward</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004&#x02013;2006</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2010</year><volume>19</volume><fpage>2437</fpage><lpage>2444</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-10-0299</pub-id><?supplied-pmid 20705937?><pub-id pub-id-type="pmid">20705937</pub-id></element-citation></ref><ref id="B31-clinpract-13-00078"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>D.C.</given-names></name>
<name><surname>Litwin</surname><given-names>M.S.</given-names></name>
<name><surname>Bergman</surname><given-names>J.</given-names></name>
<name><surname>Stepanian</surname><given-names>S.</given-names></name>
<name><surname>Connor</surname><given-names>S.E.</given-names></name>
<name><surname>Kwan</surname><given-names>L.</given-names></name>
<name><surname>Aronson</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Prostate cancer severity among low income, uninsured men</article-title><source>J. Urol.</source><year>2009</year><volume>181</volume><fpage>574</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2008.10.010</pub-id><pub-id pub-id-type="pmid">19084847</pub-id></element-citation></ref><ref id="B32-clinpract-13-00078"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McPhail</surname><given-names>S.</given-names></name>
<name><surname>Swann</surname><given-names>R.</given-names></name>
<name><surname>Johnson</surname><given-names>S.A.</given-names></name>
<name><surname>Barclay</surname><given-names>M.E.</given-names></name>
<name><surname>Elkader</surname><given-names>H.A.</given-names></name>
<name><surname>Alvi</surname><given-names>R.</given-names></name>
<name><surname>Barisic</surname><given-names>A.</given-names></name>
<name><surname>Bucher</surname><given-names>O.</given-names></name>
<name><surname>Clark</surname><given-names>G.R.C.</given-names></name>
<name><surname>Creighton</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): An International Cancer Benchmarking Partnership (ICBP) population-based study</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>587</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00127-9</pub-id><pub-id pub-id-type="pmid">35397210</pub-id></element-citation></ref><ref id="B33-clinpract-13-00078"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herbert</surname><given-names>A.</given-names></name>
<name><surname>Abel</surname><given-names>G.A.</given-names></name>
<name><surname>Winters</surname><given-names>S.</given-names></name>
<name><surname>McPhail</surname><given-names>S.</given-names></name>
<name><surname>Elliss-Brookes</surname><given-names>L.</given-names></name>
<name><surname>Lyratzopoulos</surname><given-names>G.</given-names></name>
</person-group><article-title>Cancer diagnoses after emergency GP referral or A&#x00026;E attendance in England: Determinants and time trends in routes to diagnosis data, 2006&#x02013;2015</article-title><source>Br. J. Gen. Pract.</source><year>2019</year><volume>69</volume><fpage>E724</fpage><lpage>E730</lpage><pub-id pub-id-type="doi">10.3399/bjgp19X705473</pub-id><pub-id pub-id-type="pmid">31455644</pub-id></element-citation></ref><ref id="B34-clinpract-13-00078"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McPhail</surname><given-names>S.D.</given-names></name>
<name><surname>Elliss-Brookes</surname><given-names>L.</given-names></name>
<name><surname>Shelton</surname><given-names>J.G.</given-names></name>
<name><surname>Ives</surname><given-names>A.</given-names></name>
<name><surname>Greenslade</surname><given-names>M.</given-names></name>
<name><surname>Vernon</surname><given-names>S.W.</given-names></name>
<name><surname>Morris</surname><given-names>E.J.A.</given-names></name>
<name><surname>Richards</surname><given-names>M.</given-names></name>
</person-group><article-title>Emergency presentation of cancer and short-term mortality</article-title><source>Br. J. Cancer</source><year>2013</year><volume>109</volume><fpage>2027</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.569</pub-id><pub-id pub-id-type="pmid">24045658</pub-id></element-citation></ref><ref id="B35-clinpract-13-00078"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Fletcher</surname><given-names>E.</given-names></name>
<name><surname>Denny</surname><given-names>C.S.-D.K.</given-names></name>
</person-group><source>Exploring the Role of A&#x00026;E in Cancer Diagnoses</source><publisher-name>Macmillan Cancer Support</publisher-name><publisher-loc>Albert Embankment, UK</publisher-loc><year>2018</year></element-citation></ref><ref id="B36-clinpract-13-00078"><label>36.</label><element-citation publication-type="webpage"><article-title>NHS Long Term Plan</article-title><comment>Available online: <ext-link xlink:href="https://www.longtermplan.nhs.uk/areas-of-work/cancer/" ext-link-type="uri">https://www.longtermplan.nhs.uk/areas-of-work/cancer/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-01">(accessed on 1 March 2023)</date-in-citation></element-citation></ref><ref id="B37-clinpract-13-00078"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singer</surname><given-names>D.S.</given-names></name>
</person-group><article-title>A new phase of the Cancer Moonshot to end cancer as we know it</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1345</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01881-5</pub-id><pub-id pub-id-type="pmid">35760861</pub-id></element-citation></ref><ref id="B38-clinpract-13-00078"><label>38.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>EU EC</collab>
</person-group><article-title>Communication from the Commission to the European Parliament and the Council&#x02014;Europe&#x02019;s Beating Cancer Plan. COM(2021) 44 Final Published Online First</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf" ext-link-type="uri">https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-01">(accessed on 1 March 2023)</date-in-citation></element-citation></ref><ref id="B39-clinpract-13-00078"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greenwood</surname><given-names>E.</given-names></name>
<name><surname>Swanton</surname><given-names>C.</given-names></name>
</person-group><article-title>Consequences of COVID-19 for cancer care&#x02014;A CRUK perspective</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>3</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00446-0</pub-id><?supplied-pmid 33097915?><pub-id pub-id-type="pmid">33097915</pub-id></element-citation></ref><ref id="B40-clinpract-13-00078"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faria</surname><given-names>E.F.</given-names></name>
<name><surname>Carvalhal</surname><given-names>G.F.</given-names></name>
<name><surname>Vieira</surname><given-names>R.A.</given-names></name>
<name><surname>Silva</surname><given-names>T.B.</given-names></name>
<name><surname>Mauad</surname><given-names>E.C.</given-names></name>
<name><surname>Carvalho</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Program for Prostate Cancer Screening Using a Mobile Unit: Results from Brazil</article-title><source>Urology</source><year>2010</year><volume>76</volume><fpage>1052</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2010.02.044</pub-id><pub-id pub-id-type="pmid">20472277</pub-id></element-citation></ref><ref id="B41-clinpract-13-00078"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>R.M.</given-names></name>
<name><surname>Donovan</surname><given-names>J.L.</given-names></name>
<name><surname>Turner</surname><given-names>E.L.</given-names></name>
<name><surname>Metcalfe</surname><given-names>C.</given-names></name>
<name><surname>Young</surname><given-names>G.J.</given-names></name>
<name><surname>Walsh</surname><given-names>E.I.</given-names></name>
<name><surname>Lane</surname><given-names>J.A.</given-names></name>
<name><surname>Noble</surname><given-names>S.</given-names></name>
<name><surname>Oliver</surname><given-names>S.E.</given-names></name>
<name><surname>Evans</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial</article-title><source>JAMA-J. Am. Med. Assoc.</source><year>2018</year><volume>319</volume><fpage>883</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.0154</pub-id><?supplied-pmid 29509864?><pub-id pub-id-type="pmid">29509864</pub-id></element-citation></ref><ref id="B42-clinpract-13-00078"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lynch</surname><given-names>H.</given-names></name>
<name><surname>Brodkey</surname><given-names>F.</given-names></name>
<name><surname>Guirgis</surname><given-names>H.</given-names></name>
<name><surname>Swartz</surname><given-names>M.</given-names></name>
<name><surname>Lynch</surname><given-names>J.F.</given-names></name>
<name><surname>Lynch</surname><given-names>P.</given-names></name>
</person-group><article-title>Survival data from a multiphasic mobile cancer detection unit</article-title><source>Oncology</source><year>1976</year><volume>33</volume><fpage>179</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1159/000225138</pub-id><?supplied-pmid 1018882?><pub-id pub-id-type="pmid">1018882</pub-id></element-citation></ref><ref id="B43-clinpract-13-00078"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>H.</given-names></name>
<name><surname>Ohe</surname><given-names>H.</given-names></name>
<name><surname>Inaba</surname><given-names>T.</given-names></name>
<name><surname>Itakura</surname><given-names>Y.</given-names></name>
<name><surname>Saitoh</surname><given-names>M.</given-names></name>
<name><surname>Nakao</surname><given-names>M.</given-names></name>
</person-group><article-title>A mobile mass screening unit for prostatic disease</article-title><source>Prostate</source><year>1984</year><volume>5</volume><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1002/pros.2990050511</pub-id><pub-id pub-id-type="pmid">6384977</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="clinpract-13-00078-f001"><label>Figure 1</label><caption><p>A PRISMA flow diagram of studies for inclusion in a review of mobile screening for prostate cancer.</p></caption><graphic xlink:href="clinpract-13-00078-g001" position="float"/></fig></floats-group></article>